Piper Sandler Maintains Neutral on State Street, Lowers Price Target to $75
Piper Sandler analyst Jeffery Harte maintains State Street (NYSE:STT) with a Neutral and lowers the price target from $78 to $75.
Raymond James Maintains Strong Buy on Micron Technology, Lowers Price Target to $72
Raymond James analyst Melissa Fairbanks maintains Micron Technology (NASDAQ:MU) with a Strong Buy and lowers the price target from $115 to $72.
Piper Sandler Maintains Overweight on JPMorgan Chase, Lowers Price Target to $158
Piper Sandler analyst Jeffery Harte maintains JPMorgan Chase (NYSE:JPM) with a Overweight and lowers the price target from $170 to $158.
Raymond James Maintains Strong Buy on T-Mobile US, Raises Price Target to $160
Raymond James analyst Ric Prentiss maintains T-Mobile US (NASDAQ:TMUS) with a Strong Buy and raises the price target from $158 to $160.
Piper Sandler Maintains Overweight on Citigroup, Lowers Price Target to $62
Piper Sandler analyst Jeffery Harte maintains Citigroup (NYSE:C) with a Overweight and lowers the price target from $70 to $62.
B of A Securities Downgrades ZIM Integrated Shipping to Underperform, Lowers Price Target to $40
B of A Securities analyst Muneeba Kayani downgrades ZIM Integrated Shipping (NYSE:ZIM) from Buy to Underperform and lowers the price target from $79 to $40.
Piper Sandler Maintains Overweight on Bank of America, Lowers Price Target to $47
Piper Sandler analyst Jeffery Harte maintains Bank of America (NYSE:BAC) with a Overweight and lowers the price target from $51 to $47.
Piper Sandler Maintains Underweight on Tyson Foods, Lowers Price Target to $79
Piper Sandler analyst Michael Lavery maintains Tyson Foods (NYSE:TSN) with a Underweight and lowers the price target from $85 to $79.
Atlantic Equities Upgrades First Republic Bank to Overweight, Lowers Price Target to $188
Atlantic Equities analyst John Heagerty upgrades First Republic Bank (NYSE:FRC) from Neutral to Overweight and lowers the price target from $210 to $188.
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $73
HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.